David G Warnock Selected Research

globotriaosylceramide (globotriosylceramide)

6/2022	Understanding and modifying Fabry disease: Rationale and design of a pivotal Phase 3 study and results from a patient-reported outcome validation study.
1/2022	Lyso-Gb3 associates with adverse long-term outcome in patients with Fabry disease.
4/2020	Current and Investigational Therapeutics for Fabry Disease.
12/2015	Antiproteinuric therapy and Fabry nephropathy: factors associated with preserved kidney function during agalsidase-beta therapy.
5/2015	Ten-year outcome of enzyme replacement therapy with agalsidase beta in patients with Fabry disease.
1/2012	Cardiomyopathy and response to enzyme replacement therapy in a male mouse model for Fabry disease.
12/2010	How well does urinary lyso-Gb3 function as a biomarker in Fabry disease?
9/2007	Antiproteinuric therapy and fabry nephropathy: sustained reduction of proteinuria in patients receiving enzyme replacement therapy with agalsidase-beta.
9/2006	Fabry disease: guidelines for the evaluation and management of multi-organ system involvement.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

David G Warnock Research Topics

Disease

39	Fabry Disease (Fabry's Disease) 06/2022 - 03/2005
27	Chronic Renal Insufficiency 10/2019 - 03/2003
20	Stroke (Strokes) 09/2018 - 11/2006
13	Kidney Diseases (Kidney Disease) 04/2020 - 10/2005
12	Hypertension (High Blood Pressure) 05/2018 - 09/2003
11	Acute Kidney Injury (Acute Renal Failure) 01/2021 - 10/2007
11	Inflammation (Inflammations) 10/2019 - 10/2005
10	Albuminuria 10/2019 - 10/2010
9	Type 2 Diabetes Mellitus (MODY) 10/2019 - 01/2011
8	Proteinuria 07/2015 - 01/2007
7	Chronic Kidney Failure (Chronic Renal Failure) 10/2018 - 04/2007
5	Inborn Genetic Diseases (Disease, Hereditary) 12/2021 - 05/2008
4	Disease Progression 06/2022 - 12/2010
4	Heart Failure 10/2019 - 01/2014
4	Renal Insufficiency (Renal Failure) 05/2015 - 08/2007
4	Anemia 06/2013 - 03/2003
3	Coronary Disease (Coronary Heart Disease) 07/2015 - 08/2013
3	Hemorrhage 06/2015 - 10/2005
3	Cardiovascular Diseases (Cardiovascular Disease) 05/2015 - 09/2010
3	Sepsis (Septicemia) 01/2014 - 03/2010
2	Neuralgia (Stump Neuralgia) 06/2022 - 10/2020
2	Atrial Fibrillation 01/2022 - 12/2012
2	Lysosomal Storage Diseases (Lysosomal Storage Disease) 01/2022 - 04/2020
2	Angiokeratoma 10/2020 - 04/2020
2	Pain (Aches) 10/2020 - 01/2016
2	Hypertrophic Cardiomyopathy (Hypertrophic Obstructive Cardiomyopathy) 04/2020 - 05/2015
2	Cerebrovascular Disorders (Cerebrovascular Occlusion) 04/2020 - 01/2016
2	Dyslipidemias (Dyslipidemia) 05/2018 - 01/2013
2	Insulin Resistance 05/2018 - 09/2008
2	Ischemia 02/2016 - 08/2013
2	Hypotension (Low Blood Pressure) 12/2015 - 05/2013
2	Cognitive Dysfunction 10/2014 - 12/2010
2	Fibrosis (Cirrhosis) 08/2013 - 01/2011
2	Acidosis 07/2012 - 12/2011
2	Isolated Systolic Hypertension 12/2011 - 09/2003
2	Myocardial Infarction 03/2008 - 10/2005
2	Diabetes Mellitus 04/2006 - 03/2005
2	Anaphylaxis (Anaphylactic Shock) 01/2003 - 05/2002
1	Peripheral Nervous System Diseases (PNS Diseases) 04/2020
1	Asymptomatic Diseases 01/2020
1	X-Linked Genetic Diseases 01/2020

Drug/Important Bio-Agent (IBA)

33	CreatinineIBA 01/2021 - 08/2007
23	AlbuminsIBA 10/2020 - 11/2004
12	Biomarkers (Surrogate Marker)IBA 06/2022 - 10/2005
11	GalactosidasesIBA 01/2022 - 12/2010
10	GlycosphingolipidsIBA 01/2022 - 09/2006
10	alpha-Galactosidase (Beano)IBA 01/2018 - 09/2006
10	agalsidase beta FDA Link 01/2016 - 01/2007
9	globotriaosylceramide (globotriosylceramide)IBA 06/2022 - 09/2006
8	bardoxolone methylIBA 10/2019 - 01/2011
6	Antihypertensive Agents (Antihypertensives)IBA 05/2018 - 09/2003
6	IronIBA 02/2006 - 05/2002
5	Proteins (Proteins, Gene)FDA Link 01/2020 - 02/2010
5	C-Reactive ProteinIBA 05/2018 - 04/2007
4	Hemoglobins (Hemoglobin)IBA 01/2016 - 12/2010
3	globotriaosyl lysosphingolipidIBA 01/2022 - 12/2010
3	EnzymesIBA 04/2020 - 09/2006
3	Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA 05/2018 - 01/2013
3	LipidsIBA 05/2018 - 08/2013
3	Mineralocorticoid Receptors (Mineralocorticoid Receptor)IBA 01/2014 - 10/2009
3	Dextrans (Dextran)FDA Link 03/2003 - 05/2002
2	migalastatIBA 06/2022 - 01/2015
2	Fibroblast Growth Factor-23IBA 01/2020 - 01/2011
2	Serum AlbuminIBA 10/2018 - 08/2011
2	Cystatin CIBA 10/2018 - 05/2018
2	Interleukin-6 (Interleukin 6)IBA 05/2018 - 01/2014
2	AnticoagulantsIBA 06/2015 - 07/2011
2	Warfarin (Coumadin)FDA LinkGeneric 06/2015 - 07/2011
2	LDL CholesterolIBA 05/2015 - 08/2013
2	SodiumIBA 06/2014 - 03/2003
2	PotassiumIBA 06/2014 - 05/2013
2	Epithelial Sodium ChannelsIBA 06/2014 - 09/2005
2	DiureticsIBA 05/2014 - 01/2014
2	TriterpenesIBA 01/2014 - 01/2013
2	Bicarbonates (Hydrogen Carbonate)IBA 07/2012 - 12/2011
2	Calcitriol Receptors (Calcitriol Receptor)IBA 09/2010 - 09/2008
1	TroponinIBA 10/2020
1	UromodulinIBA 01/2020
1	podocalyxinIBA 01/2020
1	Brain Form Glycogen PhosphorylaseIBA 01/2020
1	intrinsic factor-cobalamin receptorIBA 01/2020
1	MagnesiumIBA 01/2019
1	Lipocalin-2IBA 09/2018
1	CystatinsIBA 09/2018
1	Fibrinogen (Factor I)FDA Link 05/2018
1	Glucose (Dextrose)FDA LinkGeneric 05/2018
1	Glycated Hemoglobin (Glycosylated Hemoglobin)IBA 05/2018
1	Hypoglycemic Agents (Hypoglycemics)IBA 05/2018
1	Insulin (Novolin)FDA Link 05/2018
1	CholesterolIBA 05/2018
1	Blood Glucose (Blood Sugar)IBA 05/2018
1	Triglycerides (Triacylglycerol)IBA 05/2018
1	Acetylcarnitine (Alcar)IBA 05/2018

Therapy/Procedure

21	Enzyme Replacement Therapy 06/2022 - 03/2005
20	Therapeutics 04/2020 - 03/2003
4	Renal Dialysis (Hemodialysis) 01/2016 - 03/2003
3	Renal Replacement Therapy (Therapies, Renal Replacement) 01/2022 - 05/2008
2	Implantable Defibrillators (Implantable Cardioverter-Defibrillator) 01/2022 - 12/2012
2	Peritoneal Dialysis 01/2012 - 03/2003
2	Critical Care (Surgical Intensive Care) 03/2010 - 10/2007